{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prograf&page=31",
    "query": {
      "intervention": "Prograf",
      "page": 31
    },
    "page_size": 10
  },
  "pagination": {
    "page": 31,
    "page_size": 10,
    "total_count": 791,
    "total_pages": 80,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prograf&page=32&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prograf&page=30&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T03:23:56.211Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01430065",
      "title": "Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Tacrolimus in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics of ASP015K",
        "Drug Interactions",
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "ASP015K",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2009-06",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2011-09-07",
      "last_synced_at": "2026-10-26T03:23:56.211Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01430065"
    },
    {
      "nct_id": "NCT04380311",
      "title": "Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Heart Transplant Failure and Rejection"
      ],
      "interventions": [
        {
          "name": "Tacrolimus Dosing Support Tool",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Months to 18 Years"
      },
      "enrollment_count": 17,
      "start_date": "2020-05-01",
      "completion_date": "2025-04-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-26T03:23:56.211Z",
      "location_count": 2,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04380311"
    },
    {
      "nct_id": "NCT01028716",
      "title": "Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Biphenotypic Leukemia",
        "Acute Erythroid Leukemia in Remission",
        "Acute Leukemia in Remission",
        "Acute Lymphoblastic Leukemia in Remission",
        "Acute Myeloid Leukaemia With Prior Myelodysplastic Syndrome",
        "Acute Myeloid Leukemia in Remission",
        "Acute Myeloid Leukemia With FLT3/ITD Mutation",
        "Acute Myeloid Leukemia With Inv(3)(Q21Q26.2); RPN1-EVI1",
        "Acute Myeloid Leukemia With Multilineage Dysplasia",
        "Acute Myeloid Leukemia With t(6;9)",
        "Acute Undifferentiated Leukemia",
        "Adult Acute Lymphoblastic Leukemia in Complete Remission",
        "B Acute Lymphoblastic Leukemia With T(1;19)(Q23;P13.3); E2A-PBX1 (TCF3-PBX1)",
        "Ph+ ALL",
        "Burkitt Lymphoma",
        "Childhood Acute Lymphoblastic Leukemia in Complete Remission",
        "DS Stage II Plasma Cell Myeloma",
        "DS Stage III Plasma Cell Myeloma",
        "Myelodysplastic Syndrome",
        "Recurrent Anaplastic Large Cell Lymphoma",
        "Blasts Under 5 Percent of Bone Marrow Nucleated Cells",
        "Recurrent Follicular Lymphoma",
        "Recurrent Hodgkin Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Plasma Cell Myeloma",
        "Refractory Plasma Cell Myeloma",
        "Secondary Acute Myeloid Leukemia",
        "T Lymphoblastic Lymphoma",
        "Hematopoietic Cell Transplant Recipient"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 46,
      "start_date": "2010-05-19",
      "completion_date": "2021-10-07",
      "has_results": true,
      "last_update_posted_date": "2023-01-23",
      "last_synced_at": "2026-10-26T03:23:56.211Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01028716"
    },
    {
      "nct_id": "NCT03386539",
      "title": "Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pediatric Heart Transplantation",
        "Immunosuppression",
        "Chronic Kidney Diseases",
        "Cardiac Allograft Vasculopathy",
        "Heart Transplant Failure and Rejection",
        "Post-transplant Lymphoproliferative Disorder",
        "Heart Transplant Infection"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 211,
      "start_date": "2018-01-29",
      "completion_date": "2023-05-17",
      "has_results": true,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-10-26T03:23:56.211Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03386539"
    },
    {
      "nct_id": "NCT02096107",
      "title": "Novartis Everolimus Transition",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Graft Dysfunction",
        "Interstitial Fibrosis"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2014-02",
      "completion_date": "2017-05",
      "has_results": true,
      "last_update_posted_date": "2018-08-08",
      "last_synced_at": "2026-10-26T03:23:56.211Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02096107"
    },
    {
      "nct_id": "NCT07204275",
      "title": "Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Primary Membranous Nephropathy"
      ],
      "interventions": [
        {
          "name": "Povetacicept",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 176,
      "start_date": "2025-09-30",
      "completion_date": "2028-12-29",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-10-26T03:23:56.211Z",
      "location_count": 27,
      "location_summary": "Montgomery, Alabama • Surprise, Arizona • Los Angeles, California + 23 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Surprise",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Tarzana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07204275"
    },
    {
      "nct_id": "NCT00141037",
      "title": "Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Kidney Diseases",
        "Kidney Transplantation",
        "Kidney Transplant",
        "Renal Transplantation",
        "Renal Transplant"
      ],
      "interventions": [
        {
          "name": "Daclizumab",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil (MMF)",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Ganciclovir",
          "type": "DRUG"
        },
        {
          "name": "Valganciclovir",
          "type": "DRUG"
        },
        {
          "name": "Trimethoprim and sulfamethoxazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 130,
      "start_date": "2004-03",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2016-11-29",
      "last_synced_at": "2026-10-26T03:23:56.211Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00141037"
    },
    {
      "nct_id": "NCT01049633",
      "title": "B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Allogeneic Pancreatic Islet Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Basiliximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Antibacterial, Antifungal, and Antiviral Prophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Trimethoprim/sulfamethoxazole",
          "type": "DRUG"
        },
        {
          "name": "Clotrimazole",
          "type": "DRUG"
        },
        {
          "name": "Valganciclovir",
          "type": "DRUG"
        },
        {
          "name": "Heparin",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin",
          "type": "DRUG"
        },
        {
          "name": "Pentoxifylline",
          "type": "DRUG"
        },
        {
          "name": "Aspirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-06-11",
      "last_synced_at": "2026-10-26T03:23:56.211Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01049633"
    },
    {
      "nct_id": "NCT01535547",
      "title": "Drug Interaction Study of Isavuconazole and Tacrolimus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics of Isavuconazole",
        "Pharmacokinetics of Tacrolimus",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "isavuconazole",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2011-12",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2012-02-17",
      "last_synced_at": "2026-10-26T03:23:56.211Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01535547"
    },
    {
      "nct_id": "NCT02248597",
      "title": "Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft Versus Host Disease",
        "Hematopoietic/Lymphoid Cancer"
      ],
      "interventions": [
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 27,
      "start_date": "2015-02-25",
      "completion_date": "2023-01-18",
      "has_results": true,
      "last_update_posted_date": "2023-10-11",
      "last_synced_at": "2026-10-26T03:23:56.211Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02248597"
    }
  ]
}